09:56 AM EST - Oncolytics Biotech® Inc. : Announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. Oncolytics Biotech® Inc.
shares T.ONC are trading down $0.03 at $1.39.
